NCT03406650 - Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 15, 2018

Primary Completion Date

February 25, 2022

Study Completion Date

January 31, 2025

Conditions

Urothelial Cancer

Interventions

DRUG

Neoadjuvant and adjuvant durvalumab

Neoadjuvant durvalumab 1500 mg q3w for 4 cycles Adjuvant durvalumab 1500 mg q4w for 10 cycles

Trial Locations (17)

3010

Inselspital, Bern

4031

Universitaetsspital Basel, Basel

6000

Luzerner Kantonsspital, Lucerne

7000

Kantonsspital Graubünden, Chur

8032

Klinik Hirslanden - Onkozentrum Hirslanden, Zurich

8038

OnkoZentrum Zürich, Zurich

8063

City Hospital Triemli, Zurich

8091

UniversitaetsSpital Zuerich, Zurich

8401

Kantonsspital Winterthur, Winterthur

40225

Universitätsklinikum Düsseldorf, Düsseldorf

45147

Urologische Universitätsklinik Essen, Essen

CH-5001

Kantonspital Aarau, Aarau

CH-5404

Kantonsspital Baden, Baden

CH-8500

Spital Thurgau AG, Frauenfeld

CH-1211

Hopital Cantonal Universitaire de Geneve, Geneva

CH-1011

Centre Hospitalier Universitaire Vaudois CHUV, Lausanne

CH-9007

Kantonsspital St. Gallen, Sankt Gallen

All Listed Sponsors

lead

Swiss Cancer Institute

OTHER